I-Mab's Givastomig: A Potential Game Changer for Stomach Cancer Treatment
I-Mab's givastomig is a unique immune-boosting drug for stomach cancer, expected to outperform competitors, according to Leerink.
/ 2 items
I-Mab's givastomig is a unique immune-boosting drug for stomach cancer, expected to outperform competitors, according to Leerink.
US may curb Chinese drugs over national security fears, with stricter reviews for deals/data. I-Mab stock fell but is a US firm. China's biotech role is growing. White House denies active consideration of draft order.